Pharmacodynamics: Dose-Response, Receptors, and Signaling Concepts

Activators, inhibitors, and receptor concepts

Activation vs inhibition
- Activator (agonist): has intrinsic activity and can modulate/reconfigure the receptor to elicit a response.
- Inhibitor (antagonist): sits on the receptor and prevents the natural ligand from interacting; does not have intrinsic activity on its own.
Agonist concepts
- Agonist: produces a full functional response when bound.
- Partial agonist: binds with affinity and has intrinsic activity but produces a submaximal (partial) response compared to a full agonist.
- Inverse agonist: has intrinsic activity that reduces constitutive (basal) receptor activity; can toning down activity of receptors that have constitutive activity.
Practical clinical questions tied to pharmacodynamics
- How does a dose-response curve look in presence of an inhibitor vs a stimulator?
- How to compute starting doses and safety profiles across populations?
- How to define therapeutic concentration windows and safety margins?
- These concepts lay the foundation for systems pharmacology and later lectures.

Dose-response curves: key definitions and interpretation

Dose-response curve basics
- A curve that plots the degree of response against increasing doses (or concentrations) of a drug.
- Usually sigmoidal to allow easier determination of potency and efficacy.
- Example given: acetylcholine as a natural ligand that induces muscle contraction; plot dose vs response.
Potency vs efficacy
- Potency: information gleaned from the concentration (or dose) required to reach a given response; commonly summarized by the EC$_{50}$.
- Efficacy: the maximum response a drug can produce (the height of the curve).
Key definitions and quantities
- EC$_{50}$: concentration that produces 50% of the maximal response. Represents potency.
- $EC_{50}$ = concentration producing 50% of maximal response.
- E$_{max}$: maximum response achievable by the drug (efficacy).
- ED$_{50}$: dose that produces a beneficial response in 50% of the population (population-based potency/efficacy metric).
- $ED_{50}$ = dose producing therapeutic effect in 50% of individuals.
- TD$_{50}$: dose that induces a toxic effect in 50% of the population (toxicity endpoint).
- $TD_{50}$ = toxic dose for 50% of individuals.
- Therapeutic index (TI): safety measure comparing toxic and beneficial doses.
- TI = rac{TD{50}}{ED{50}}
- Therapeutic window: the dose range between the minimum effective dose and the dose that produces toxicity; a guide to safe dosing.
Cumulative dose-response curve (ED${50}$ and TD${50}$ context)
- A population-based cumulative graph shows, at increasing doses, the cumulative number of responders.
- ED$_{50}$ is read from the dose at which 50% respond beneficially.
- TD$_{50}$ is read from the dose at which 50% show toxicity.
- This helps define safe dosing ranges and the therapeutic window.

Inhibitors and how they alter dose–response curves

In presence of an inhibitor, you can distinguish between:
- Competitive (reversible) inhibitor: competes with the agonist for the same receptor site (orthosteric site).
- Effect on curve: potency is reduced; the curve shifts to the right (higher dose/concentration needed to achieve the same effect).
- Efficacy (E$_{max}$) remains the same if the inhibitor is truly competitive and reversible; you can overcome inhibition by increasing the agonist concentration.
- Example concept: acetylcholine with a competitive antagonist shifts EC${50}$ to a higher value; E${max}$ unchanged.
- Noncompetitive (often irreversible) inhibitor: binds to a different site or inactivates the receptor, reducing the maximal response.
- Effect on curve: E$_{max}$ is reduced; potency may appear unchanged or less affected depending on scenario; overall efficacy falls.
- If inhibition is irreversible, increased agonist concentration cannot restore E$_{max}
Allosteric modulation vs orthosteric competition
- Allosteric modulators bind to an allosteric site (not the orthosteric site) and change receptor response to the endogenous ligand.
- Positive allosteric modulators (PAMs) enhance the effect of the endogenous ligand; negative allosteric modulators (NAMs) dampen it.
- These are not traditional competitive inhibitors; they modify the response without directly competing for the same binding site.
Examples and concepts discussed
- Competitive inhibitor example: shifts EC${50}$ to the right; E${max}$ unchanged.
- Noncompetitive inhibitor example: reduces the height (E${max}$) of the curve; may or may not shift EC${50}$.
- Inverse agonist behavior: can modulate baseline activity and shift the curve accordingly (downward shift of activity when constitutive activity exists).
Reversibility and clinical implications
- Reversible inhibitors: efficacy can be recovered by increasing agonist dose.
- Irreversible inhibitors: lower E$_{max}$ and may not be overcome by higher agonist levels; associated with toxicity risks and historically higher toxicity when used (e.g., certain irreversible inhibitors).
- Practical takeaway: choice between reversible vs irreversible inhibitors has major safety and therapeutic implications.

Partial agonists and inverse agonists: nuances and examples

Partial agonist
- Has affinity and intrinsic activity but yields a partial response compared to a full agonist.
- If used alone, produces partial efficacy; in the presence of a full agonist, it can act as an antagonist by competing for receptor binding.
- Clinical examples mentioned: pindolol (beta receptor partial agonist) used to temper excessive beta-1 stimulation (e.g., during high endogenous epinephrine) without causing excessive bradycardia.
- Buprenorphine is another classic example for mu-opioid receptors, providing pain relief with lower risk of full opioid effects and less respiratory depression than morphine.
Inverse agonist
- Has intrinsic activity that reduces constitutive receptor activity.
- Classic example: histamine H2 receptor (toning down constitutive activity at H2); some cases (like GABA-A receptor) can be modeled with inverse agonism to study effects such as increased anxiety when constitutive activity is suppressed.
- Clinically, inverse agonists are not broadly used for GABAergic systems; they can be useful for modeling anxiety in animals.
Graphical implications
- Partial agonist alone yields a lower maximum response than full agonist.
- Inverse agonist shifts the baseline activity downward if there is constitutive activity; in systems with constitutive activity, this can reduce the observed response below baseline.

Allosteric modulators: sites, roles, and graph interpretation

Allosteric vs orthosteric sites
- Orthosteric site: the active binding site where the endogenous ligand binds.
- Allosteric site: a distinct site where other ligands bind to modulate receptor activity.
Positive allosteric modulators (PAMs)
- Bind allosterically and enhance the effect of the endogenous ligand.
- Example: diazepam (a benzodiazepine) as a positive allosteric modulator of the GABA-A receptor.
- Effect on dose–response curves: can enhance potency and/or efficacy of the endogenous ligand; not a simple competitive inhibition.
Negative allosteric modulators (NAMs)
- Bind allosterically and reduce receptor activation by the endogenous ligand.
How to interpret graphs with allosteric modulators
- The presence of a PAM/NAM changes the curve in a non-competitive manner (not simply shifting the orthosteric competition). Depending on the system, PAMs can shift the apparent EC$_{50}$ and/or change the maximal response in the presence of the endogenous ligand.
Practical example context
- GABA-A with diazepam as PAM is a clinically relevant case; the drug alters receptor opening probability in the presence of GABA.

Receptor families and their signaling frameworks

Receptors and targets overview
- Membrane receptors (accessible targets):
- G protein-coupled receptors (GPCRs): large family; >800 members; >500 FDA-approved drugs act via GPCRs.
- Receptor tyrosine kinases (RTKs): growth factor receptors; activation leads to dimerization, transphosphorylation, and kinase signaling cascades.
- Ion channels: ligand-gated ion channels (e.g., nicotinic acetylcholine receptors, GABA-A receptors) and voltage-gated channels.
- Intracellular receptors (less accessible; typically lipid-soluble ligands):
- Nuclear receptors such as estrogen receptor, thyroid hormone receptor; action via transcriptional regulation after ligand binding and receptor translocation to the nucleus.
GPCR signaling (illustrative examples)
- Core architecture: receptor on the membrane binds ligand; receptor acts as a G protein-coupled receptor that interacts with a heterotrimeric G protein (Gαβγ).
- G protein cycle:
- Inactive: Gα bound to GDP with βγ subunits attached.
- Activation: ligand binding promotes GDP→GTP exchange on Gα; Gα-GTP dissociates from βγ and activates downstream effectors.
- Transducers and second messengers depend on Gα subtype:
- Gs (stimulatory): activates adenylyl cyclase → increases cAMP → activates PKA.
- Gq: activates phospholipase C (PLC) → generates IP$_3$ and DAG → Ca$^{2+}$ signaling and PKC activation.
- Example pathways:
- β2-adrenergic receptor (Gs): endogenous ligand epinephrine; airway smooth muscle relaxation via cAMP signaling (used in asthma therapy with beta-2 agonists such as albuterol/salbutamol).
- Muscarinic M3 receptor (Gq): airway smooth muscle contraction via PLC/IP$_3$/DAG signaling; antagonists can prevent contraction.
Receptor tyrosine kinases (RTKs)
- Mechanism: ligand binding induces receptor monomer dimerization, extracellular domain brings two units together, intracellular domains transphosphorylate (transphosphorylation).
- Downstream signaling involves cascades like MEK-ERK (MAPK pathway), leading to proliferation, migration, and other responses.
- Therapeutic angle: monoclonal antibodies can block ligand-receptor interactions; small molecules can target downstream kinases (e.g., MEK) to interfere with signaling.
Ion channels
- Classic examples: nicotinic acetylcholine receptor (ion channel); GABA-A receptor (chloride channel).
- GABA-A: opening of Cl$^-$ channels hyperpolarizes neurons, producing inhibitory effects; diazepam (PAM) enhances GABA-A receptor activity.
- Response times: ion channels are among the fastest responses (milliseconds).
Intracellular receptors
- Cortical/epithelial/intracellular targets respond through transcriptional regulation; slower onset due to needs for transcription and translation (hours to days).
Non-receptor targets
- Many drugs also target intracellular enzymes and signaling molecules such as kinases (e.g., MAP kinases), and thus modulate signaling cascades directly rather than receptor binding.
Cytokine receptors and related pathways
- Cytokines (e.g., TNF-α, IL-6) signal via receptors that can resemble RTK or other surface receptors; some share downstream pathways with GPCR signaling or activate JAK-STAT cascades.
- Inflammation and signaling illustrate diversity of receptor families and the variety of pharmacologic targets.

Receptor sensitization, desensitization, and withdrawal considerations

Desensitization and downregulation as a homeostatic response
- Overstimulation leads cells to desensitize to limit continuous signaling.
- Mechanisms include receptor downregulation and post-translational modification (e.g., phosphorylation by downstream kinases).
Homologous vs heterologous desensitization
- Homologous desensitization: desensitization of a receptor due to its own persistent stimulation.
- Heterologous desensitization: when stimulation of one receptor subtype leads to desensitization of another receptor type, due to shared signaling resources (e.g., kinases, second messengers).
Resource depletion and signaling crosstalk
- Chronic stimulation can deplete mediators and signaling components, reducing responsiveness.
Antagonist/withdrawal considerations
- Chronic antagonist exposure can lead to upregulation of receptors (receptor supersensitivity).
- Abrupt withdrawal after chronic antagonist use (e.g., propranolol, a beta-blocker) can cause rebound overactivation due to increased receptor density.
- If a long-term antagonist is tapered, abrupt withdrawal can lead to exaggerated responses due to upregulated receptors.
Clinical implications
- When chronic inhibition is used, tapering or gradual withdrawal may be necessary to avoid rebound effects.
- Receptor desensitization and upregulation influence drug efficacy over time and can necessitate dose adjustments.

Practical takeaways and clinical relevance

Summary of major concepts from today
- Definitions: activator vs inhibitor; agonist, partial agonist, inverse agonist; competitive vs noncompetitive inhibitors; allosteric modulators (PAM/NAM).
- Dose-response curves: EC${50}$ (potency), E${max}$ (efficacy), ED${50}$ (population-based potency), TD${50}$ (toxicity), therapeutic index TI, and therapeutic window.
- Receptor types and signaling: GPCRs, RTKs, ion channels, intracellular receptors; signaling basics and timescales.
- Desensitization and withdrawal: homologous vs heterologous desensitization; up/down regulation and clinical implications for tapering.
Practical clinical bearings
- When choosing between two drugs with similar potency and efficacy, TI (safety margin) can guide selection.
- Reversible vs irreversible inhibitors have different safety profiles; irreversibility tends to raise toxicity risk.
- Allosteric modulators offer alternative routes to modulate receptors with potential for improved selectivity and safety.
- Understanding signaling pathways helps predict drug interactions and side effects (e.g., GPCRs vs RTKs vs ion channels).
Look ahead
- Next topic: pharmacokinetics, including absorption, distribution, metabolism, and excretion, and how these influence pharmacodynamics in real patients.